Medicine and Dentistry
Liver Transplantation
100%
Cohort Analysis
76%
Kidney Graft
62%
Transplantation
53%
Nonalcoholic Fatty Liver
50%
Liver Cirrhosis
49%
Quality of Life
41%
Machine Perfusion
35%
Liver Graft
30%
Disease
27%
Proton-Pump Inhibitor
24%
Metabolic Syndrome
24%
Hepatitis C
23%
Prevalence
22%
Liver Disease
21%
Gut Microbiome
20%
Fatty Liver
19%
Clinical Trial
18%
Amyloidosis
18%
Population
18%
Arm
17%
End Stage Liver Disease
17%
Transthyretin
17%
Thrombosis
17%
Antiviral Therapy
17%
Cardiovascular Disease
16%
Adverse Event
16%
Trimethylamine
15%
Hepatocellular Adenoma
15%
Liver Fibrosis
15%
Branched Chain Amino Acid
15%
Non-Alcoholic Fatty Liver Disease
15%
Iron Deficiency
15%
Antivirus Agent
15%
Maturity Onset Diabetes of the Young
15%
All Cause Mortality
12%
Cholestasis
11%
Gut
11%
Biological Marker
11%
Blood Stasis
11%
Diagnosis
11%
Infusion
11%
Dysbiosis
11%
Anemia
10%
Homeostasis
10%
Insulin Resistance
10%
Hemostat
10%
Long Term Survival
10%
Patient-Reported Outcome
9%
Body Mass Index
9%
Keyphrases
Kidney Transplant Recipients
62%
Non-alcoholic Fatty Liver Disease (NAFLD)
47%
Health-related Quality of Life
44%
Proton Pump Inhibitors
39%
Biobank
32%
Solid Organ Transplant Recipients
25%
Fatty Liver Index
24%
Transplantation
23%
Orthotopic Liver Transplantation
23%
All-cause Mortality
21%
Iron Deficiency
21%
Liver Transplant Recipients
20%
Gut Microbiome
18%
Tacrolimus
18%
Metabolic Syndrome
17%
Metabolic-associated Fatty Liver Disease (MAFLD)
16%
Liver Transplantation
16%
Cirrhosis
16%
Branched-chain Amino Acids
15%
Daily Functioning
15%
End-stage Liver Disease
15%
Extracellular Vesicles
15%
Netherlands
14%
Cardiovascular Disease
13%
Type 2 Diabetes Mellitus (T2DM)
13%
Hepatic Steatosis Index
11%
Nonalcoholic Steatohepatitis
11%
Dutch
11%
Low-density Lipoprotein
10%
Transplant Recipients
10%
Obesity
10%
Gut Dysbiosis
10%
Liver
10%
Disease Groups
9%
High Prevalence
9%
Solid Organ Transplantation
9%
Tremor
9%
C-reactive Protein
9%
Cause-specific Mortality
9%
Cirrhotic Patients
9%
Kidney Transplantation
9%
Prospective Cohort Study
9%
Long-term Survival
9%
Population-based Cohort
8%
End-organ Disease
8%
Whole Blood
8%
Chronic Use
8%
Cardiovascular Risk
8%
Mortality Risk
8%
Hypothermic Machine Perfusion
7%
Pharmacology, Toxicology and Pharmaceutical Science
Nonalcoholic Fatty Liver
80%
Cohort Study
72%
Liver Cirrhosis
39%
Fatty Liver
37%
Proton Pump Inhibitor
31%
Prevalence
21%
All Cause Mortality
19%
Disease
19%
Antivirus Agent
18%
Metabolic Syndrome X
18%
Tacrolimus
17%
Hepatitis C
15%
Liothyronine
15%
Palmitic Acid
15%
Liotrix
15%
Anticoagulant Agent
15%
Cardiovascular Disease
15%
Iron Deficiency
15%
Ethanol
14%
Omeprazole
12%
Cardiovascular Risk
11%
Liver Fibrosis
10%
Clinical Trial
10%
Liver Disease
10%
Observational Study
10%
Lipotoxicity
10%
Therapeutic Drug Monitoring
9%
Thyrotropin
9%
Infection
9%
Lipoprotein
9%
C Reactive Protein
8%
Adverse Event
8%
Clinical Study
8%
Esomeprazole
8%
Insulin Resistance
8%
Hepatitis C Virus
8%
Fibrosis
8%
Mycophenolic Acid
7%
Disease Course
7%
Immune Checkpoint Inhibitor
7%
Metformin
7%
Blood Stasis
7%
Apolipoprotein B
7%
Hesperetin
7%
Calgranulin
7%
Illicit Drug
7%
Retinol
7%
Hepatotoxicity
7%
Pharmacogenomics
7%
Ganciclovir
7%
